Differential Amperometric Microneedle Biosensor for Wearable Levodopa Monitoring of Parkinson's Disease

Levodopa (L-Dopa) is considered to be one of the most effective therapies available for Parkinson's disease (PD) treatment. The therapeutic window of L-Dopa is narrow due to its short half-life, and long-time L-Dopa treatment will cause some side effects such as dyskinesias, psychosis, and orthostatic hypotension. Therefore, it is of great significance to monitor the dynamic concentration of L-Dopa for PD patients with wearable biosensors to reduce the risk of complications. However, the high concentration of interferents in the body brings great challenges to the in vivo monitoring of L-Dopa. To address this issue, we proposed a minimal-invasive L-Dopa biosensor based on a flexible differential microneedle array (FDMA). One working electrode responded to L-Dopa and interfering substances, while the other working electrode only responded to electroactive interferences. The differential current response of these two electrodes was related to the concentration of L-Dopa by eliminating the common mode interference. The differential structure provided the sensor with excellent anti-interference performance and improved the sensor's accuracy. This novel flexible microneedle sensor exhibited favorable analytical performance of a wide linear dynamic range (0-20 mu M), high sensitivity (12.618 nA mu M-1 cm(-2)) as well as long-term stability (two weeks). Ultimately, the L-Dopa sensor displayed a fast response to in vivo L-Dopa dynamically with considerable anti-interference ability. All these attractive performances indicated the feasibility of this FDMA for minimal invasive and continuous monitoring of L-Dopa dynamic concentration for Parkinson's disease.

Automated summary

L-Dopa is an effective therapy for Parkinson's disease, but its short half-life and narrow therapeutic window may lead to side effects. Monitoring the concentration of L-Dopa using wearable biosensors is significant to reduce complications. However, the high concentration of interferents in the body poses challenges. A minimal-invasive L-Dopa biosensor based on a flexible differential microneedle array (FDMA) is proposed to address this. The sensor exhibits excellent anti-interference performance and accuracy.